Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Account Payables (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Change in Account Payables for 4 consecutive years, with -$591000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 21.93% to -$591000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$118000.0, a 97.56% increase, with the full-year FY2024 number at -$1.5 million, up 37.78% from a year prior.
  • Change in Account Payables was -$591000.0 for Q3 2025 at Century Therapeutics, down from -$365000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q3 2023 to a low of -$3.0 million in Q1 2023.
  • A 4-year average of -$614200.0 and a median of -$591000.0 in 2025 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: skyrocketed 465.72% in 2023, then crashed 265.37% in 2024.
  • Century Therapeutics' Change in Account Payables stood at -$1.6 million in 2022, then crashed by 76.79% to -$2.9 million in 2023, then surged by 116.52% to $477000.0 in 2024, then tumbled by 223.9% to -$591000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Change in Account Payables are -$591000.0 (Q3 2025), -$365000.0 (Q2 2025), and $361000.0 (Q1 2025).